Picture of Coherus Biosciences logo

CHRS Coherus Biosciences Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousSmall CapSucker Stock

Momentum

Relative Strength (%)
1m+7.05%
3m-6.79%
6m-61.29%
1yr-72.09%
Volume Change (%)
10d/3m-61.09%
Price vs... (%)
52w High-72.14%
50d MA-4.22%
200d MA-32.28%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-53.99%
Return on Equityn/a
Operating Margin-88.02%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202331st Dec 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of Coherus Biosciences EPS forecast chart

Profile Summary

Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development, and commercialization of immunotherapies to treat cancer. It operates in the business of developing and commercializing the human pharmaceutical products segment. The Company’s product pipeline comprises three product candidates, toripalimab, an anti-PD-1 antibody being developed in collaboration with Junshi Biosciences; CHS-006, an antibody targeting TIGIT being developed in collaboration with Junshi Biosciences; and one wholly owned preclinical immuno-oncology program, CHS-1000, an antibody targeting ILT4. The Company markets UDENYCA (pegfilgrastim-cbqv), a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor, in the United States (the U.S). It also sells CIMERLI (ranibizumab-eqrn), a biosimilar of Lucentis, in the U.S. The Company also focused on developing Humira, a biosimilar YUSIMRY (adalimumab-aqvh) in the U.S.

Directors

Last Annual
December 31st, 2022
Last Interim
September 30th, 2023
Incorporated
September 29th, 2010
Public Since
November 6th, 2014
No. of Shareholders
26
No. of Employees
299
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNASDAQ Global Market
Shares in Issue
111,364,152

CHRS Share Price Performance

Upcoming Events for CHRS

Q1 2024 Coherus BioSciences Inc Earnings Release

Coherus BioSciences Inc Annual Shareholders Meeting

Q2 2024 Coherus BioSciences Inc Earnings Release

Similar to CHRS

Picture of 89bio logo

89bio

us flag iconNASDAQ Global Market

Picture of Abivax SA logo

Abivax SA

us flag iconNASDAQ Global Market

Picture of AC Immune SA logo

AC Immune SA

us flag iconNASDAQ Global Market

Picture of Acrivon Therapeutics logo

Acrivon Therapeutics

us flag iconNASDAQ Global Market

Picture of Adagene logo

Adagene

us flag iconNASDAQ Global Market

FAQ